The common goal is the advancement of women’s health and welfare, through tackling the most burdensome crisis facing the female population, such as cervical cancer.
NTL Healthcare, a company specializing in obstetrics and gynecology, has tied up with Huons Medical. NTL Healthcare Co., Ltd. (CEO Taehee Kim), a company specializing in obstetrics and gynecology, announced that it had signed a business agreement with Huons Medical Co., Ltd. (CEO Lee Seung-yong) on the exclusive distribution rights of JILL'SOF™ and V-Needle™ in Korea. Through this agreement, NTL Healthcare has been able to exclusively distribute Huons Medical's JILL'SOF™ and is operating for obstetrics and gynecology hospitals and clinics nationwide. JILL'SOF™ and V-Needle™ are women-only medical devices developed to inject drugs into the affected part of the vagina, while JILL'SOF™ is equipped with automatic pressure-sensing injection system and specialized hardware for intravascular procedures. In addition, it is possible to set the drug injection amount and injection speed, so that a customized treatment for each patient is possible. The V-Needle™ is a special needle for JILL'SOF™ designed to allow for more accurate and faster drug injection into the affected area. Through this business alliance, which combines Huons Medical's technology with NTL Healthcare's obstetrics and gynecology network, it is expected that the speed of the spread of JILL'SOF™ will gain momentum. Kim Tae-hee, CEO of NTL Healthcare said, “I think JILL'SOF™...
admin ㆍ 2021.06.03 ㆍ Votes 0 ㆍ Views 18
NTL Healthcare Co., Ltd. announced on the 31st that it had signed a strategic business partnership agreement with Cardinal Health Korea Co., Ltd. to strengthen its obstetrics and gynecology business. NTL Healthcare (CEO Taehee Kim), a company specializing in obstetrics and gynecology, signed a business agreement with Cardinal Health Korea (CEO Scott Brian Zimmerman) to expand sales of SCD Sleeve. On the 28th, at the signing ceremony of the business agreement held at Cardinal Health Korea headquarters in Joong-gu, Seoul, NTL Healthcare CEO Kim Tae-hee, Cardinal Health Korea CEO Cho Seung-je, and Han Jong-su director attended. The SCD Sleeve (limb compression circulatory device) is a therapeutic material that prevents the death of patients due to pulmonary artery pulmonary embolism (PE) by preventing lower extremity edema, varicose veins, and deep vein thrombosis (DVT) occurring before and after childbirth. It is characterized by checking blood flow and providing sequential compression for each part with a customized pressure for each patient. Through this agreement, both companies will conduct joint marketing to strengthen their sales of obstetrics and gynecology and focus on selling the SCD Sleeve. Kim Tae-hee, CEO of NTL Healthcare, said "We are happy to supply the world's best products through an...
admin ㆍ 2021.06.03 ㆍ Votes 0 ㆍ Views 21
NTL Healthcare participates in 'Arab Health 2021'. NTL Healthcare (CEO Taehee Kim, a company specialized in obstetrics and gynecology, announced that it would participate in the ‘Dubai International Medical Equipment Show (Arab Health 2021, hereafter referred to as Arab Health)’. ‘Arab Health 2021 (connections.arabhealthonline.com/event/arab-health)’ is considered one of the world's top three medical device exhibitions along with the International Medical Device Exhibition (MEDICA) in Germany, and more than 3,500 exhibitors and 52,000 participants from 159 countries will visit this year. This event will be held in two ways: an online event to be held from May 23rd to July 22nd (local time) and an offline event to be held at the Dubai World Trade Center from June 21st to 24th (local time). NTL Healthcare participates in a non-face-to-face online exhibition and introduces a medical device, Dr. Cervicam C20Ⓡ (TelecervicoⓇ) and medical software, CerviCAREⓇ. Dr. Cervicam C20Ⓡ is a cervix magnifying device that magnifies the cervix by up to 50 times to diagnose cervical cancer early, and can check the results of evaluation by a gynecologist within 24 hours. The accuracy of the cervical cancer screening results of the cervical magnification test (TelecervicoⓇ) reaches 94.1%. In addition, CerviCARE® is a program...
admin ㆍ 2021.06.03 ㆍ Votes 0 ㆍ Views 25
NTL celebrated its 25th anniversary. NTL, a company specializing in obstetrics and gynecology, announced that it held a founding ceremony for executives and employees in the company to celebrate the 25th anniversary of its foundation. The event, in which more than 100 executives and employees participated, was held in a way that minimized face-to-face meetings to prevent the spread of Covid-19 and social distance. Starting with the screening of the 25th anniversary video and commemorative video, the event was held in the order of long-term service awards and commendations from exemplary employees and excellent departments in the first quarter. Celebratory videos and commemorative videos were filmed by employees themselves, and contain the history and celebrations of NTL, which celebrated its 25th anniversary. A total of five people, including two 10-year employees, received the long-term service award. The executives and employees were given refreshment leave and rewards according to the number of years they worked. The exemplary employees were selected as other exemplary employees and received certificates and rewards, and the excellent team was selected as the marketing team that demonstrated smooth cooperation with other departments and exceptional ability to perform their work. Shin Hyeon-soo, president of the NTL Medical Institute,...
admin ㆍ 2021.05.10 ㆍ Votes 0 ㆍ Views 77
NTL Healthcare introduced new Artificial Intelligence (AI) technology at the ‘2021 AI EXPO KOREA’. NTL Healthcare (CEO, Tae-hee Kim) participated in ‘2021 AI EXPO KOREA’ held at COEX in Samseong-dong, Seoul for 3 days from 24th to 26th and unveiled “CerviCARE AI,” a cervical cancer screening system. The CerviCARE AI is a system that utilizes 6 million cervical imaging big data that NTL has accumulated over the past 25 years, and it classifies the normal into normal and abnormal, as well as negative and positive evaluation of cervix. Abnormal created a learning model that was subdivided into low-grade lesion, high-grade lesion, and cancer, and conducted more than 300,000 data verification. In addition, NTL applied for medical device license (grade 3) approval from the Ministry of Food and Drug Safety based on the results of clinical trials in Korea for domestic and foreign screening services of CerviCARE AI. NTL introduced “CerviCARE AI” at the AI EXPO KOREA and had a time to communicate with visitors by questioning and answering questions. NTL Healthcare provides various screening services such as screening for women’s cancer not only cervical cancer, and has plans to continue to develop and supply new products that can improve women’s...
admin ㆍ 2021.04.26 ㆍ Votes 0 ㆍ Views 124
We, NTL HEALTHCARE has participated as an exhibitor at the MENA region’s largest exhibition for healthcare and trade professionals from 27th – 30th January 2020 in Dubai, UAE. Arab Health is where the world of healthcare meets. Staging 15 exhibitions and 110 conferences, creating the largest global healthcare database, supporting 10,000 exhibitors and reaching over 700,000 healthcare professionals. Arab Health is at the very heart of the sector.
ntlnoida ㆍ 2021.03.15 ㆍ Votes 0 ㆍ Views 135
Out of 33,531 Korean women, 4,117 women who have done cytology testing, HPV testing and biopsy together had the NTL's Telecervico test for two years from January 2015 to December 2016. This research had identified the most effective method of screening for cervical cancer for the discovery of high-grade lesions (CIN2+). The sensitivity of the Telecervico examination was 81.3%, which was higher than Pap smear test 54.1%, and HPV test 74.9%. Also, false negative was 18.7%, so this research says that it is recommended to do Telecervico test for the screening of cervical cancer.
ntlnoida ㆍ 2021.03.15 ㆍ Votes 0 ㆍ Views 105
European Journal of Obstetrics.pptx Among 4,117 women who simultaneously or subsequently underwent Pap cytology, HPV test, cervicography, colposcopically directed biopsy, cervicography and Pap co-testing had superior screening capacity (sensitivity: 97.5% vs 93.7%) and cost-effectiveness (cost: $1,474 vs $1,135) for detection of pre-invasive cervical lesions than HPV and Pap co-testing and may be an effective and cost saving screening strategy in clinical practice in country with a high prevalence of cervical cancer.
ntlnoida ㆍ 2021.03.15 ㆍ Votes 0 ㆍ Views 105
NTL Medical Institute (CEO Shin, HyeonSu) conducted volunteer medical services at the Migrant Workers' shelter located in Yongin on the third of March, 2019. Migrant workers' shelter is a place where workers from foreign countries to relax and receive education on how to settle down in Korea. Many of them are unable to receive medical insurance benefits, even though they are ill. The volunteer group of the NTL Medical Institute consists of a "medical team" and a "support team," which collects the blood and urine of migrant workers and provides free medical services for diagnostic tests to determine the presence of various diseases. Participants who attended the service said, "At first, it was difficult to adjust because of prejudice, but it was more rewarding through migrant workers who actively opened their minds to medical services. In the future, we want to do more volunteer work by visiting migrant workers' shelters."
ntlnoida ㆍ 2021.03.15 ㆍ Votes 0 ㆍ Views 99
‘2017 Korea Business Award’ hosted by Moneytoday was held on March 31st in Press center, Jung-gu, Seoul. From this event, Adipolabs received the new technology award, MDimune, Ben’s Lab, and NTL received Bio award. NTL Medical Institute is a woman cancer expertized corporate which exports wireless cervicography device abroad, such as the Czech, India, Thailand, and Mongolia, as the industry-first. The existing cervical cancer screening test accuracy stays only at 50~60%, however, accuracy of the wireless TeleCervico is 92~95%. NTL said that the incidence of cervical cancer has decreased from the 1st place of woman cancer to 7th place, and this result is due to NTL’s considerable effort to generalize the cervical cancer screening test.
ntlnoida ㆍ 2021.03.15 ㆍ Votes 0 ㆍ Views 109